1st Department of Obstetrics and Gynecology, University of Athens, Athens, Greece.
Int J Gynecol Cancer. 2009 Dec;19(9):1614-9. doi: 10.1111/IGC.0b013e3181ae3f40.
Heparanase is an endoglycosidase that specifically cleaves heparan sulfate side chains of heparan sulfate proteoglycans, the major proteoglycans in the extracellular matrix and cell surfaces. Traditionally, heparanase activity was implicated in cellular invasion associated with angiogenesis, inflammation, and cancer metastasis. More recently, heparanase up-regulation was documented in an increasing number of primary human tumors. Iotan this study, we sought to investigate the expression of heparanase messenger RNA (mRNA) in normal cervical tissue and intraepithelial cervical lesion and its clinicopathologic importance in invasive cervical cancer. Gene expression of heparanase was assessed by quantitative real-time reverse transcriptase polymerase chain reaction in 28 normal cervical, 26 intraepithelial neoplastic, and 48 cervical cancer tissue samples. Heparanase mRNA expression was different between the 3 groups and lower in normal cervical specimens in relationship with intraepithelial cervical lesions and invasive cervical cancer tissue samples (P = 0.048). Gradually increasing expression of heparanase was evident as the cells progressed from low-grade to high-grade squamous intraepithelial lesions (P = 0.002). In invasive cervical cancer cases, there was a direct correlation between heparanase expression and tumor size (P = 0.002). In cases treated with radical hysterectomy and pelvic lymphadenectomy, the heparanase mRNA expression was significantly higher in tumors exhibiting lymph vascular space invasion (P = 0.044) and in cases with big tumor size (P = 0.005). In our study, we did not find any significant correlation between disease-free and overall survival rates and expression of heparanase (P = 0.396 and P = 0.712, respectively). The results of this study suggest that the gene expression of heparanase in cervical cancer enhances growth, invasion, and angiogenesis of the tumor and may have therapeutic applications.
乙酰肝素酶是一种内切糖苷酶,它特异性地切割乙酰肝素硫酸侧链的乙酰肝素硫酸蛋白聚糖,这是细胞外基质和细胞表面的主要蛋白聚糖。传统上,乙酰肝素酶活性与血管生成、炎症和癌症转移相关的细胞侵袭有关。最近,越来越多的原发性人类肿瘤中发现乙酰肝素酶的上调。在这项研究中,我们试图研究乙酰肝素酶信使 RNA(mRNA)在正常宫颈组织和上皮内宫颈病变中的表达及其在浸润性宫颈癌中的临床病理意义。通过定量实时逆转录聚合酶链反应评估 28 例正常宫颈、26 例上皮内瘤变和 48 例宫颈癌组织样本中的乙酰肝素酶基因表达。乙酰肝素酶 mRNA 表达在 3 组之间存在差异,正常宫颈标本中的表达低于上皮内宫颈病变和浸润性宫颈癌组织样本(P = 0.048)。随着细胞从低级别鳞状上皮内病变进展到高级别鳞状上皮内病变,乙酰肝素酶的表达逐渐增加(P = 0.002)。在浸润性宫颈癌病例中,乙酰肝素酶表达与肿瘤大小之间存在直接相关性(P = 0.002)。在接受根治性子宫切除术和盆腔淋巴结切除术治疗的病例中,在表现出淋巴血管空间侵犯的肿瘤中,乙酰肝素酶 mRNA 表达显著更高(P = 0.044),在肿瘤较大的病例中(P = 0.005)。在本研究中,我们没有发现乙酰肝素酶表达与无病生存率和总生存率之间存在任何显著相关性(P = 0.396 和 P = 0.712,分别)。本研究的结果表明,宫颈癌中乙酰肝素酶的基因表达增强了肿瘤的生长、侵袭和血管生成,并且可能具有治疗应用。